that microRNA-145 (miR-145) expression decreases with the progression of PACa, allowing aberrant expression of MUC13. Restitution of lost levels of miR-145 may prevent PACa progression by down-regulating MUC13 expression. Design: A pilot study using six-week-old athymic Nu/nu mice was carried out to investigate the effect of miR-145 restitution. Mice were divided into three treatment groups,control (six mice), non-targeting control mimics (NC, six mice) and miR-145 (six mice). Tumors in mice were implanted by injecting PACa HPAF-II cells, having high MUC13 expression, into the right flank subcutaneously. After the tumors developed, (avg. volume 80 mm 3 ) miR-145 mice group was injected intratumorally with miR145 mimics 9 times. Tumor growth was followed for 21 days until the tumors reach 700 mm 3 . The mice were then euthanized followed by the analysis of tumor growth, volume and metastasis. Tumor volumes were examined as a function of time (discreet), group (control, NC, and interaction between them.
. Hierarchical analysis of genes differentially expressed (green-over, red-under) in HER2 subtype compared to control, ER/PR+ (desiganated as LUM) or TN groups. Conclusions: We identified unique gene signatures expressed differently in HER2+ DCIS, which may be associated with development of IBC. The result may enhance our understanding of the mechanisms of breast cancer progression and become the basis for developing new predictive biomarkers and/or therapeutic targets. providing calcium infl ux. ORAI3 is involved in the proliferation of lung cancer cells. In breast cancer, it has been reported that ORAI3 is an estrogen receptor α (ERα) and that EGF-regulates its activity. Moreover, both ERα and EGFR play a signifi cant role in the growth of lung carcinomas. Design: Immunohistochemistry was performed on 200 samples of primitive lung AC (ORAI3, 1:100, Sigma ; ERα, SP1, Ventana ; EGFR, 3C6, Ventana). Staining levels were determined by subjective visual scoring by two operators independently.The aim was to investigate the ORAI3 expression in primitive lung AC (n=200) in relation to ERa and EGFR and its potential relevance to clinicopathological variables and prognosis. Results: ORAI3 staining was present in 66.5% (N=133/200) of AC. Statistical analysis showed that overexpression of ORAI3 was signifi cantly associated with tobacco use, necrosis tumor, visceral pleura invasion, ERα expression and EGFR status. The Kaplan-Meier survival analysis showed that the expression of ORAI3 was related to the poor overall survival (OS) (expression, N=133/200, 40 .71 months vs no expression, N=67/200, 95.6 months; p<0.001) and metastatic progression-free survival (MP-FS) (expression, N=133/200, 27 .21 months vs no expression, N=67/200, 69.52 months; p<0.001) of patients with lung AC. Multivariate Cox analysis showed that ORAI3 was an independent prognostic factor for both OS and MP-FS. Conclusions: We highlight the major role of ORAI3 regulation by ERα and EGFR in lung AC. We show, for the fi rst time, that the overexpression of ORAI3 was associated with tobacco use, histological variables and poor prognosis in lung AC and thus may serve as a new molecular marker to predict the prognosis of lung AC patients.
Design: The Cancer Genome Atlas (TCGA), which catalogues mutations found in cancer genomes was used to analyze somatic mutations. We utilized deposited exome data of 6,014 patients and analyzed the mutation status of all 33 Mediator subunits in 22 different human cancer types. Non-synonymous mutations were considered for analysis. SNPnexus web server (http://www.snp-nexus.org) was used to retrieve pre-computed SIFT and Poly-Phen2 predictions of the probability of an amino acid substitution affecting protein function. Results: We found a unique mutational landscape, identifying the kinase and tail as hot spots across all cancers. Furthermore, a recurrent mutation in MED12L was found across six cancer types whereas two recurrent mutations in MED15 were detected in fi ve cancer types. Multiple mutations across different subunits within a tumor specimen were observed. Mutations in MED12, MED12L, MED13 and MED13L show the highest numbers of connectivity to mutations in other subunits of the Mediator complex. Also mutations in the kinase module of the Mediator subunit result mainly in a damaging protein function. Conclusions: Our systematic and comprehensive analysis reveals, for the fi rst time, the mutational landscape of the whole Mediator complex in cancer, and suggests that mutations are frequently found in the kinase module of the Mediator but also are widespread among different tumor entities.
Two-Staged Approach in Identifying Therapeutic Targets for Patients With Advanced Cancers
Russell Broaddus, Beate Litzenburger, Kenna Shaw, J Jack Lee, Walter Kinyua, Blessy Sajan, Mark Routbort, Keyur Patel, Rajyalakshmi Luthra, Rajesh Singh, Scott Kopetz. University of Texas MD Anderson Cancer Center, Houston, TX. Background: The effi cacy of small next generation sequencing (NGS) panels for the initial therapeutic management of patients with solid tumor malignancies is established, especially for melanoma, colorectal cancer, and lung cancer. The utility of such panels for identifying therapeutic targets after front-line therapies have failed is less clear. We initiated a prospective study to assess the utility of systematic identifi cation of potential therapeutic targets by NGS in patients with advanced solid tumor malignancies. A twostaged molecular diagnostics approach was used in which the patients were initially evaluated with a 50 gene next generation sequencing (NGS) panel (CMS50) that analyzes for hot spot mutations. If no therapeutic trials were identifi ed based on the CMS50 testing, or if the patient suffered recurrence following an initial targeted therapy trial, a next generation sequencing panel of 409 full exomes (CMS400) was employed. Design: To be eligible for the expanded CMS400 panel, patients had to have completed standard front-line therapy, have a performance status of 0 or 1, and be agreeable to participation in a clinical trial if a possible therapeutic target was identifi ed. All NGS was performed on formalin-fi xed, paraffi n-embedded tumors. An interim analysis was performed after the fi rst 117 patients to determine the initial clinical utility. Clinically actionable was defi ned as a somatic mutation for which a matched genotype selected therapeutic clinical trial exists. Actionable mutations had associated functional data demonstrating that they could be targeted by a specifi c agent. Results: For 24% of patients (28/117), at least one mutation in a targetable gene was identifi ed in the initial CMS50 screen. Overall, CMS400 identifi ed 96 mutations in actionable genes. 44% of patients (51/117) had at least one mutation in an actionable gene identifi ed by the more expanded testing that was not identifi ed in the initial screen. 29% of these patients (15/51) had mutations that were known to have functional impact. The functional signifi cance of the remaining somatic mutations is currently unknown. Conclusions: Expanded molecular testing does provide benefi t by identifying more patients who are potentially eligible for targeted therapy trials. Most of the specifi c mutations identifi ed, while in actionable genes, have unknown functional impact. At this point, only the patients with variants known to have functional impact are enrolled in clinical trials. Once the relevance of these other variants is better defi ned, it is likely that more of these patients can be enrolled in trials.
Molecular Mechanisms of Prevention of Septic Acute Respiratory Distress Syndrome By Airway Pressure Release Ventilation
Tiffany Caza, Kerry Whiting, Michaela Kollisch-Singule, Sumeet Jain, Joshua Satalin, Kathleen Snyder, Louis Gatto, Frank Middleton, Penny Andrews, Gary Nieman, Nader Habashi, Steve Landas. SUNY Upstate Medical University, Syracuse, NY; SUNY Cortland, Cortland, NY; University of Maryland School of Medicine, Baltimore, MD. Background: Acute respiratory distress syndrome (ARDS) is refractory to treatment once established and the only therapy is supportive mechanical ventilation. Preemptive application of airway pressure release ventilation (APRV) prevents ARDS in animal models and in a human trial by preserving surfactant, reducing pulmonary edema, and minimizing alveolar microstrain. Molecular mechanisms underlying protection in APRV-protected lung are unknown. The purpose of this study is to elucidate mediators of lung protection through a genome-wide gene expression analysis. Design: Pigs were anesthetized and instrumented. Fecal peritonitis was established by SMA clamping then release for 30 min to induce an ischemia/reperfusion injury. Pigs were randomized to early ARDSnet (n=3) with TV 6 mL/kg, PEEP 5cmH 2 O, F i O 2 21% and titrated according to the low PEEP or early APRV (n=3) with P High 16cmH 2 O, P Low 0cmH 2 O, T High 4.5 s, T Low set to terminate the peak expiratory fl ow at 75% and F i O 2 21%. After 48h, necropsy was performed. RNA was extracted from lung, cDNA synthesized, and hybridized on Affymetrix porcine gene 1.0 ST arrays. Microarrays were analyzed by Ingenuity Pathway Analysis. Gene expression at the <5 or >95 percentile with a p value of <0.05 were considered signifi cant. Results: APRV prevented ARDS. APRV activates TGFb1 and targets that negatively regulate infl ammation (p=1.3 x 10 -7 ). APRV-treated lung tissue had reduced expression of transcripts promoting leukocyte, NK, and CTL function and downregulation of downstream cytokines IFNγ and IL-15 (cluster p=6.6 x 10 -6 ). APRV reduced expression of transcripts that reduce apoptosis and promote survival in endothelial cells, regulated by AGT, C5, CSF2, IL-1, SMAD3, and VEGF, and endothelin 1 (p=3.1 x 10 -6 of cluster). APRV enhances expression of genes encoding surfactant by 52-382 percent. Matrix metalloproteinase (MMP) transcripts are reduced by ≥50%.
Conclusions: APRV prevents development of ARDS secondary to ischemia-reperfusion injury and sepsis by reducing infl ammation, endothelial cell apoptosis, and MMPmediated breakdown of the ECM. Conclusions: While we recognize that this is a small cohort, but this work is intriguing for the new information it provides on genomic abnormalities in kn-ALL. Our data highlights important role of SNP microarray technology in understanding the fundamental aspect of leukemogenesis especially in those cases which are clinically labeled with a normal karyotype. We are in the process to expanding the study by including additional kn cases of ALL. Background: By using a combination of array-based comparativegenomic hybridization and genomic sequencing, a number of recurrent mutations have been identifi ed in pediatric acute lymphoid leukemia (ALL). The most commonly targeted genes were PAX5, EBF1, and IKZF. A number of other rarer lesions were also identifi ed, including focal deletions confi ned to the genomic loci chr3q12-13 containing CD200 and BTLA in about 7% of ALLs. Design: By mapping the breakpoint of these deletions in primary ALL blasts, the deletions resulted in the loss of both CD200 and BTLA in all but one case. Moreover, analyzing the sequence at the breakpoints suggested that deletion was the result of aberrant RAG-mediated recombination. Importantly, no point mutations in CD200 or BTLA were detected in any of the analyzed pediatric ALL cases, suggesting that haploinsuffi ciency of these two genes was likely to contribute to leukemogenesis.
To explore whether loss of both genes contributes to leukemogenesis, we crossed mice heterozygous for a Cd200-null allele (Cd200 +/-) with mice heterozygous for a Btla-null allele (Btla +/-) to generate mice that were heterozygous for both genes (Cd200+/-: Btla+/- Background: Accurate diagnosis of an early neoplastic lesion has a major implication in patient management. Diagnosing borderline, low or high grade dysplasia, or early carcinoma has been a major challenge. Substantial interobserver diagnostic variation emphasizes the need for routinely applicable marker(s) as an adjunct to histological diagnosis. Endoscopic mucosal resection (EMR) specimen is the best source to learn about the process. We tested EMR specimens with a panel of markers. Design: Seven gastric adenocarcinoma(CA) and 5 esophageal squamous cell CA(SCA) obtained by EMR specimens were tested for the expression of p53, Ki-67, minichromosome maintenance proteins (Mcm2), β-catenin, cyclin D1 and p16 by immunohistochemistry, together with 3 colon adenoCA, 19 adenomas (7tubulovillous, 6 tubular, and 6 serrated ) and 6 hyperplastic polyps of colon. Tubulo-villous adenomas were used as positive controls for the immunoreaction of dysplastic cells. Study cases were interpreted by comparison with controls. Only strongly stained columnar cells in continuity (not scattered) were considered positive. Only cytoplasmic p16, nuclear cyclin D1,Mcm2 and P53, and cytoplasmic and /or nuclear β-catenin were considered positive. Results: P53, Mcm2 and cyclin D1 stains in EMR colocalized with the dysplastic area and showed clear delineation from low (LGD) and high grade(HGD) dysplasia to CA and uniformly strong positive staining in CA, distinct from the adjacent atypical or normal areas. TVA showed strong and uniform staining, while tubular adenomas showed heterogenous reaction admixed strong and weak staining. Serrated adenoma showed positive staining in the basal crypts, labeling extended from the lower crypts to the surface, easily distinguishable from normal and hyperplastic polyps. p53 stains were negative in 2 of 7 (28.6%) gastric adenoCA and 1 SCA (20%). Ki-67 stains was less-specific than that of Mcm2. β-catenin staining was mostly cytoplasmic in LGD and focally lost or cytoplasmic with occasional nuclear staining in the area of HGD/CA. p16 cytoplasmic expression was present in 60% of HGD/CA but weak and spotty in LGD. Design: Primary THL cell line as named CS-THL1 was established from an 85 yearold lymphoma patient. Immunohistochemistry (IHC) was conducted to determine the levels of MYC, BCL2, BCL6, or Ki-67 expression in formalin-fixed, paraffin-embedded tissues. MTS assay were employed to evaluate the anti-growth efficacy of 10058-F4, JQ-1, ABT-199 in CS-THL1 and DoGKiT cell alone or together and with or without vincristine or doxorubicin exposures. Flow cytometric analysis of propidium iodide and Annexin V and/or 7AAD stained cells or cytochrome c release was performed to assess apoptosis. Intracellular expression of BCL2, BCL-xL, BIM, and MCL-1 protein was analyzed by flow cytometry. Results: As shown by IHC analysis, expression of MYC, BCL2, BCL6 and proliferation factor Ki67 was increased in THL. Analysis of cell viability demonstrated that inhibition of MYC by 10058-F4 or JQ-1 or BCL2 by ABT-199 as a single agent significantly inhibited the growth of CS-THL1 and DoGKiT cells in a dose and time-dependent manner. In addition, combination of 10058-F4 or JQ-1 and ABT-199 or together with vincristine or doxorubicin synergistically attenuated the growth of CS-THL1 and DoGKiT cells compared with single agent treatment. Moreover, using multiple approaches, we demonstrated that apoptosis induced by the inhibition of anti-apoptotic BCL2 with ABT-199 and the inhibition of strong growth promoting factor MYC with 10058-F4 or JQ-1 was the underlying cause of the observed growth retardation. Conclusions: These observations suggest that concurrent inhibition of MYC and BCL2 pathway signaling is a promising treatment strategy for patients with aggressive DH and TH B-cell lymphomas. Background: The incidence of renal cell carcinoma (RCC) has doubled due to increased detection of asymptomatic small renal masses (SRMs). There are no clinical or radiographic features able to predict the behaviour of SRMs. Non-invasive prognostic biomarkers able to predict aggressive behaviour are urgently required. Design: We performed label-free quantitative liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) urine peptidomics analysis on 6 patients with progressive and 6 with non-progressive with clear cell RCC-SRM as well as 6 matched normal urines. Bioinformatic analysis was performed to identify significantly altered pathways.
Conclusions

Platelet Cloaking of Cancer Cells Inhibits Immune Surveillance
Results:
We identified 1,963 unique endogenous urine peptides arising from 392 proteins. Initial comparative analysis identified 227 unique peptides in non-progressive disease and 289 unique peptides in progressive disease. Endogenous peptides from monocyte differentiation antigen CD14 (CD14), serotransferrin (TF), fibronectin 1 (FN1), filamin A (FLNA), and aminoacylase 1 (ACY1) were only identified in urine from patients with progressive clear cell RCC-SRMs. Pathway analysis identified CD14 to be a positive regulator of tumor necrosis factor production (p=0.0016) and associated with NF-kB signalling (p <0.01). In addition, pathway analysis identified TF as a positive regulator of the platelet-derived growth factor receptor signalling pathway (p<0.0001), endothelial cell proliferation (p<0.01), protein kinase B signalling (p<0.01), angiogenesis (p<0.01), and epithelial cell proliferation (p=0.01). FN1 was shown to be involved in cell-matrix adhesion (p<0.01) as well as migration processes such as angiogenesis (p=0.01) and wound healing (p=0.027). FLNA has a role in epithelial to mesenchymal transition (EMT) (p<0.01) as well as the G-protein coupled receptor signalling pathway (p<0.01) and NF-kB signalling pathway (p<0.01). Furthermore, pathway analysis found ACY1 to have a role in cellular amino acid metabolism (p=0.018). Conclusions: Taken together, CD14, TF, FN1, FLNA, and ACY1 represent potential prognostic biomarkers able to distinguish between patients with progressive and nonprogressive RCC-SRMs. Background: Cancer is morphologically and genetically heterogeneous and the Pan-Cancer Analysis Project aimed to identify the genomic changes present in 12 cancer types from the Cancer Genome Atlas (TCGA) set. We aimed to identify predictors of the 5 main differentiation subtypes in the Pan-Cancer Analysis and a general molecular grading for epithelial malignancies. Design: Whole exome sequencing was performed on tumor and normal tissue samples from 3129 patients enabling the identification of cancer related mutations in each patient. Clinical data were also collected for all patients, including gender and age. We used a Random Forest machine learning approach to compare the 5 differentiation subtypes in a pairwise fashion and a low (grade 1-2) vs. high (grade 3-4) grade. Functional somatic mutations unique to tumors were identified and represented as a samples x genes mutation matrix (mutated=1, non-mutated=0). &#9658; Pairwise Random Forest models were built for the 5 cancer differentiation subtypes (Adenocarcinoma, Squamous, Urothelial, Brain, Hematological) &#9658; Recursive feature selection was used in a 5x10 fold cross validation design. Random Forest models were based on the training set using the caret package in R &#9658; Predictive accuracy of each model was measured in an independent test set.
Functional Mutation Signatures of 5 Cancer Differentiation Subtypes and Epithelial Tumor Grading: Utility of Exome Sequence Data and Random Forest Analysis
Results:
We were able to discriminate between Bladder Urothelial Cancer and Acute Myeloid Leukemia in unseen samples with 87.8% accuracy (95% CI : (78.71, 93.99), Specificity 0.77 Sensitivity 0.94 AUC 0.9677) 5 binary predictors of tumor class membership of Urothelial or Hematological subtypes and epithelial grading (low vs. high). Average accuracy in the other comparisons is 85.0% &#9658; Using a 5 variable random forest ensemble classification model (MLL3, TTN, ARID1A, MLL2, FRG1B), we achieved near 90% accuracy in class assignment task (after excluding any statistically significant gender and age bias between the high grade and low grade tumors) and identifying high grade carcinomas (glandular, squamous and urothelial). Grade-predictive genes included ARID1A, CTCF, CTNNB1, PIK3CA, PIK3R1, PTEN, and TP53.
Conclusions: Exome sequence provide reliable data to classify common malignancies and may be clinically useful for the subtyping of malignancies and grading of carcinomas in case of limited tissue (i.e. biopsies). We now aim to produce a 5-class subtyping and 2-tier grading prediction models to assign test samples prospectively.
Microscopic Colitis Associated With Inflammatory Bowel Diseases Is Characterized By Increased Th1 and TNFα-Producing Cells in Colonic Mucosal Lamina Propria
Xianyong Gui, Ji Li, Yuchu Yan, Shuhong Liu, Andrew Flynn, Paul Beck, Subrata Ghosh. University of Calgary, Calgary, AB, Canada; Peking Union Medical College Hospital, Beijing, China. Background: An association between microscopic colitis (MC), i.e. lymphocytic colitis (LC) and collagenous colitis (CC), and inflammatory bowel diseases (IBD) has been noted. A subset of MC cases evolve into IBD, either ulcerative colitis (UC) or Crohn's disease (CD). IBD in remission may present a histologic pattern of MC. MC and IBD can coexist in different regions of bowel. All of these suggest a link between MC and IBD in their pathogenesis. Abnormal mucosal immunity is likely the key. Design: We reviewed totally 2324 MC cases in Calgary region over 14 years and identified a small number of IBD-related cases in 2 subgroups: 1)MC evolved into IBD, 13 cases (5 LC-CD, 3 LC-UC, 1 LC-IBDU, 2 CC-UC, 2 CC-IBDU), 2) mixed MC and IBD, 5 cases (2 LC/CD, 1 LC/UC, 1 CC/UC, 1 LC/IBDU). They were further investigated for their colonic mucosal lamina propria mononuclear cells, as opposed to 20 cases (LC 10, CC 10) that were quickly resolved after treatment. The first colonic biopsies of these cases were retrieved and immunohistochemistry was used to detect various T cell subsets characterized by key cytokines and master transcription factors (IFNγ and T-bet for Th1, IL-13 and Gata3 for Th2, IL-17 and RoRgt for Th17, FoxP3 for Treg) as well as TNFα + cells (partly representing Th1). The lymphocytes positive for each marker were counted (average number per HPF of 5 to 10 HPFs). Results: Overall, as compared to the normalized cases, the IBD-related cases showed a significantly higher population of Th1-type cells including IFN-γ + (20.07 ± 11.80 vs 13.92 ± 8.12) and T-bet + cells (158.66 ± 52.36 vs 122.35 ± 48.31), and TNF-α + cells (19.97 ± 18.35 vs 11.18 ± 10.85). (p < 0.01 for all). This difference was particularly seen in cases that evolved into IBD (subgroup 1). In addition, this subgroup had more Gata-3 + (Th2) cells (283.12 ± 75.98 vs 219.87 ± 45.32, p < 0.01). No difference existed between the two groups for Th17 (ROR-gt + and IL-17 + ), Treg (FoxP3 + ), and IL-13 + cells. Within the normalized cases, more TNF-α + and ROR-gt + cells, but no difference for other subsets, were seen in LC than that in CC cases. Conclusions: Th1 and TNFα-producing cells, and likely a subset of Th2 (Gata-3 + ) cells as well, may be involved in the MC cases that are associated with IBD transformation.
Additional KRAS, NRAS and BRAF Mutations Revealed By Next Generation Sequencing Cancer Gene Panel: Necessity of Comprehensive Mutation Detection for Scrutinizing Colorectal Cancer Candidates for Epidermal Growth Factor Receptor (EGFR) Targeted Therapy
Ruifeng Guo, Jesse Voss, Jennifer Winters, Sarah Kerr, Kevin Halling, Benjamin Kipp. Mayo Clinic, Rochester, MN. Background: EGFR targeted therapies have been combined with standard chemotherapy regimens for treatment of metastatic colorectal cancer (CRC) in patient's whose tumors lack KRAS mutations. In 2012, the FDA approved a theranostic mutation test covering 7 mutations in codons 12 and 13 of KRAS only. However, more recent data suggests that expanded "RAS" testing to include alternate mutant codons in KRAS, BRAF, and NRAS may better predict whether patients will respond to EGFR targeted therapies. The goal of this study was to assess the clinical utility of running a 50 gene cancer panel (including the expanded RAS coverage) versus the FDA-approved KRAS test in a clinically tested cohort of patients with CRC. Design: Mutation data was retrospectively collected from 132 consecutive CRC patients undergoing routine clinical testing with a 50 gene next generation sequencing (NGS) cancer panel, which included expanded testing of KRAS, NRAS and BRAF genes. All variants detected with the primary panel were verified using an orthogonal NGS test. Results: Pathogenic mutations were detected in 96% of cases, and 57% had mutations in KRAS, BRAF and/or NRAS genes ( Figure 1) . Overall, 25% of tested patients had a KRAS, BRAF or NRAS activating mutation that would not have been detected by the FDA approved KRAS assay, including alternate KRAS mutations (10%), NRAS mutations (3%), BRAF V600E mutation (10%) and BRAF non-600 mutations (2%).
In addition, 39% of specimens had mutations in genes other than RAS/RAF genes.
Conclusions:
The FDA approved KRAS single gene assay does not detect a significant portion of RAS/RAF mutations known to be associated with non-response to EGFR inhibitors. As a result, using only the FDA approved test will result in non-efficacious, expensive, and potentially harmful anti-EGFR therapy treatments for a significant fraction of CRC patients. These results suggest that all tumors from patients being considered for treatment with EGFR inhibitors should, at minimum, be tested for mutations using expanded RAS/RAF coverage.
Synergistic Effect of EZH2 Knockdown and Irradiation Against Pancreatic Cancer Cells
Raavi Gupta, Raag Agrawal, Laura Martello-Rooney, M Haseeb. SUNY Downstate Medical Center, Brooklyn, NY; SUNY Downstate, Brooklyn, NY. Background: Pancreatic ductal carcinoma is the fourth leading cause of cancer-related death, with a 5-year survival rate below 5%; mostly due to advanced-stage diagnosis, relative scarcity of treatment options, and resistance to chemotherapy. Therefore, development of novel treatment approaches, including targeted treatment as an adjuvant modality or as a radiosensitizer, are urgently needed. EZH2 is a catalytic subunit of a histone methyltransferase and is involved in transcriptional repression of genes involved in cell proliferation. EZH2 has been implicated in several aggressive cancers including pancreatic carcinoma. The use of small interfering RNA (siRNA) to downregulate its expression has been explored as a therapeutic option in multiple tumors. Here we explore the antitumor effect of siRNA knockdown of EZH2 on pancreatic cancer cells when applied in combination with irradiation. Design: EZH2 expression was evaluated in human pancreatic adenocarcinoma tissue sections (n=10) and in human pancreatic carcinoma cells (PANC1) by immunohistochemistry. PANC1 cells were seeded and allowed to adhere for 24 hrs before transfection. At 72 hrs post-transfection, the cells were γ-irradiated (4 Gy) and left undisturbed for 6 hrs before plating or harvesting for various assays. Cell cycle analysis of propidium iodide-stained cells was performed by flow cytometry at 6 hrs after irradiation. Western blot analysis for EZH2 expression was performed on 3, 5 and 7 days post-transfection. Cell proliferation assays were performed at 24, 48, 72 and 96 hrs following irradiation. Results: All of the human pancreatic adenocarcinomas and PANC1 cells were strongly positive for EZH2. siRNA-EZH2 downregulated EZH2 expression by 90%. Western blot showed the knockdown of EZH2 levels in transfected cells at 72 hrs post-transfection and the day of irradiation. EZH2 knockdown arrested the cells in the G2/M phase as compared to control siRNA-treated cells. The combination of siRNA-EZH2 and irradiation led to cell cycle arrest at G2/M and increased apoptosis. An increase in the number of floating cells was noted in the combination treatment of EZH2 knockdown and irradiation. Conclusions: These results suggest that siRNA mediated knockdown of EZH2 together with radiation induces a therapeutic effect in PANC1 cells as determined by cell proliferation, cell cycle progression and apoptosis. Combination therapies using radiotherapy and gene silencing may prove useful in treating pancreatic carcinoma.
Histologic Characterization of Tumors With "No Reportable
Alteration" By Next-Generation Sequencing James Gurp, Christine Minerowicz, Betty Chung, Marina Chekmareva, Lauri Goodell, Hua Zhong. Rutgers Robert Wood Johnson Medical School and Rutgers Cancer Institute of New Jersey, New Brunswick, NJ. Background: Next-generation sequencing (NGS) is a powerful technique to acquire high-throughput data on genetic alterations in various malignancies. The FoundationOne pan-cancer NGS panel interrogates the entire coding sequence of 236 cancer-related genes plus 47 select introns from 19 genes involved in fusion. These genes are demonstrated to be somatically altered in many human solid cancers. However, reportable alterations are not identified in every malignancy. Design: Surgical pathology formalin-fixed paraffin embedded tumor specimens from 179 patients seen at our institution since November 2012 were sequenced by NGS using the FoundationOne platform at a depth of 500-1,000X. Histopathological features of all specimens with "No Reportable Alteration" were analyzed. Results: 11 out of 179 cases (6.1% of total 186 specimens) returned results of "no reportable alteration". One case had three specimens tested. All paraffin blocks had adequate viable tumor tissue based on the FoundationOne standard. These 11 cases included 4 female and 7 male patients with a median age of 34.9 years (range: 3-56 years). Specimen interval from collection to NGS ranged from 0.5 to 41 months (median 1.5 months). Specimen sites included soft tissue (4), lymph node (3), lung (2), colon (1) and brain (1). Specimen types were known in 10 cases, including resection (5), excisional biopsy (3), core biopsy (1) and fine needle aspiration cell block (1). These 11 cases included 4 soft tissue sarcomas (synovial sarcomas, desmoplastic small round cell tumor, rhabdomyosarcoma), 2 neuroblastomas, 1 angioimmunoblastic T-cell lymphoma, 1 metastatic poorly differentiated squamous cell carcinoma of unknown primary, 1 metastatic medullary thyroid carcinoma, and 1 well-differentiated neuroendocrine carcinoma. In comparison with cases with reportable alterations, this group of patients were younger and had tumors predominately originating from mesenchymal, neuroectodermal, or neuroendocrine origins. Conclusions: Certain tumor types, such as those arising from mesenchymal, neuroectodermal, or neuroendocrine origin may have alterations currently unknown or not covered by current pan-cancer NGS panels but potentially reportable. Increasing the breadth of sequencing (whole exome sequencing) or applying more focused approaches on select cases (using sarcoma or hematopoietic panels) may uncover more useful and clinically-oriented data in these types of cases. DNA promoter methylation leading to gene silencing is one mechanism implicated in acquired endocrine-resistance, but remains poorly understood. Accordingly, we compared DNA methylation in paired primary and recurrent breast tumors to elucidate markers and mechanisms that may be associated with therapy failures and potential targets for targeted therapies. Design: A total of 70 breast tumor tissue blocks were obtained including 25 matched primary and recurrent pairs. DNA was extracted from 3 macro-dissected FFPE tissue sections per tumor and methylation was assessed using the Illumina HM450 BeadChip. Methylation of primary and recurrent tumors, sorted by ER status, were compared using Mean β values (degree of methylation). Results: Among all primary tumors, ER+ tumors had higher mean β values than ERtumors. Furthermore, ER+ primary tumors from women with an ER+ recurrence(n = 34 tumors) showed slightly greater mean methylation than the ER+ primary tumors from women with an ER-recurrence(n = 13 tumors). However, in this group(ER+ primary to ER-recurrent), methylation was significantly increased in the ER-recurrent tumors. Specifically, 97% of the top deferentially methylated CpGs(dmCpGs) in the set showed greater methylation in the ER-recurrent tumor as compared to the ER+ primary tumor.
In contrast, when both primary and recurrent were ER+, only 57% of the top dmCpGs showed increased methylation in the recurrent tumor. Likewise, when both primary and recurrent were ER-, only 29% of top dmCpGs were more methylated in the recurrent. Among the top CpGs in ER-recurrent tumors from women who had ER+ primary tumors, only two CpGs had decreased methylation in the recurrent tumors: Both were in AFF3, a gene shown to be upregulated in breast cancer. Heat map analysis of AFF3 reveals an overall methylation increase in the ER-recurrent tumors, with the greatest increase occurring in promoter and 5'UTR regions.
Conclusions:
To our knowledge, this is the first report showing that DNA methylation is significantly increased in ER-recurrent tumors occurring in women whose primary breast tumor was ER+. However, our results confirm earlier reports of greater methylation associated with ER+ as compared to ER-breast tumors. These observations may affect selection of patients for treatments targeting gene methylation.
Comparison of Protein Biomarker Expression in Bronchoalveolar Lavage (BAL) Between Primary Lung Adenocarcinoma and Squamous
Cell Carcinoma To Improve Detection of NSCLC Sarah Karram, Susan Geddes, Frederic Askin, Edward Gabrielson, Hui Zhang, Qing Kay Li. Johns Hopkins Medical Institutions, Baltimore, MD. Background: Following the findings of the National Lung Cancer Screening Trial (NLST), the detection of lung cancers has been substantially improved with the use of highly sensitive low-dose computed tomography (LDCT). However, NLST also found high repeat screening rates and high false-positive rates, causing unnecessary secondline invasive procedures and/or surgery. New strategies are still needed to improve the specificity of lung cancer screenings. Bronchoalveolar lavage (BAL) is commonly used for the cytological evaluation of lung parenchymal cells in patients with a suspicion for lung cancer. Our preliminary study has shown that proteins in the BAL fluid can be analyzed to identify potential protein biomarkers. In this study, we have further evaluated the protein signature between lung adenocarcinoma (ADC) and squamous cell carcinoma (SqCC), and the potential utility of these signatures as biomarkers for the diagnosis of lung cancers. Design: BAL samples from patients with benign lung disease, lung adenocarcinoma, and lung squamous cell carcinoma, were collected and analyzed by using SPEG and LC-MS/ MS techniques. After initial identification, we further tested sensitivity and specificity of a subset of proteins using independently-collected BAL specimens by ELISA assays. Results: A total of 462 glycoproteins were identified and quantified from BAL fluids of both ADC and SqCC patients . Among them, 290 proteins were identified in the BAL of lung ADC, 376 in lung SqCC, and 318 in benign BALs. In addition to proteins found in all groups, we identified 123 unique proteins that were differentially expresssed exclusively in either benign disease, ADC or SqCC. The levels of several proteins in cancer and benign BALs were further validated by ELISA assays, using an independently collected subset of BAL specimens. Most notably among these proteins, periostin was significantly elevated in cancer BAL specimens compared to levels seen in benign lung diseases. Conclusions: Proteins in the airway fluid (i.e. BAL fluid) from lung cancer patients can be detected by a highly sensitive proteomic approach. They can be used as protein biomarkers to enhance the detection of lung cancers, therefore improving the specificity of lung screening tests. Background: Expectorated human oral fluid (a.k.a. saliva, spit) is a popular, facile, non-invasive specimen for constitutional genome sequencing, epigenomic analyses, epidemiological studies, and nucleic-acid-based detection of pathologic conditions. Despite the prevalence of oral fluid molecular profiling, there are few published reference values for cellular composition in routine expectorated oral fluid DNA extracts; in addition, CpG methylation reference levels based on a large population of individuals are not well established for detecting constitutional or malignancy-associated epimutations as may be present in oral fluid. Design: Oral fluid DNA methylation profiles from >300 specimens were derived from bisulfite microarray analysis of >450K CpG targets, for cellular composition and proportions, and for methylation levels of several genes subject to epimutation in the human population. Results: Principal component analysis was consistent with a two-lineage mixture of leukocytes and buccal mucosal epithelial cells (BECs), and further showed that leukocytes outnumber desquamated epithelial cells several fold. Additional comparisons incorporating purified lymphoid and myeloid white blood cell subsets revealed that the oral fluid leukocyte component is largely derived from neutrophils (PMN), while lymphocyte-specific epialleles were essentially undetectable by DNA methylation microarray in whole oral fluid DNA extracts.
Conclusions: Thus, oral fluid molecular profiling captures the same predominant cell component as blood-the neutrophil--while epithelial cells comprise ~20%. Differentially methylated targets contributing to oral fluid composition are significantly enriched for enhancers of genes that function in leukocyte and epithelial cell biology. Pediatric versus adult age, but not sex, was found to have a significant correlation with the epithelial/leukocyte ratio in oral fluid. Overall, our results demonstrate that expectorated oral fluid is a biological resource with a definable cell composition and copious DNA yields, and provide reference values for leukocyte and epithelial fractions for molecular profiling studies. Additionally, oral fluid DNA methylation reference databases are useful assets for estimating population frequency of constitutional epialleles/epimutations. (7), adenoid cystic carcinoma (5), B cell lymphomas and leukemias (3), breast adenocarcinoma (2), melanoma (1), lung adenocarcinoma (1), and carcinoma of unknown primary (1). One adenoid cystic carcinoma had dual gain-of-function mutations, a pattern previously described only in T-ALL, and all 5 Notch-mutated adenoid cystic carcinomas had high-grade features. In evaluable cases, gain-of-function mutations were associated with high levels of activated Notch in tumor cells, judged by IHC staining. By contrast, loss-of-function mutations were seen in 1.8% of tumors (71 tumors total), of which 46 (65%) were squamous cell carcinomas arising from skin, oropharynx, lung, anus, and salivary gland. The large majority of sequence variants (85%) were in-frame SNVs of uncertain significance that mapped throughout Notch1 and Notch2. Conclusions: These findings are consistent with the emerging view that Notch can function as either an oncogene or a tumor suppressor in a context-specific fashion. Gain-of-function mutations are enriched in T-ALL, peripheral B cell tumors, and adenoid cystic carcinoma, whereas loss-of-function mutations are prevalent in squamous cell carcinoma. Most sequence variants are of uncertain functional significance and may be passenger mutations acquired stochastically during tumor evolution and progression. Of the 40 most frequently mutated genes, 12 (30%) encoded epigenetic regulators, including histone modifying (MLL, CREBBP), chromatin remodeling (ARID1B, ARID2), active DNA demethylation (TET2, IDH1), and microRNA processing (DICER1) enzymes. Among the 26 melanoma samples, 25 (96.2%) harbored at least one mutation in an epigenetic regulator. In addition, mutations to epigenetic genes had the highest frequency of C to T transitions, reflecting putative UVB damage.
Targeted Next Generation Sequencing of Treatment-Naïve Metastatic Melanoma Specimens Reveals High Frequency of Epigenetic Alterations
Conclusions:
Our study provides direct genomic evidence that epigenetic regulators involved in various mechanisms and processes may be involved in the pathobiology of melanoma. In addition we identified that MECOM, a novel chromatin remodeling/ transcription modifying enzyme, and TET2/IDH1, critical enzymatic and metabolic regulators of DNA demethylation, are more frequently mutated in patient metastatic melanoma samples than previously reported. Filtering against the 1000 Genomes data set and a local database of common polymorphisms and sequencing artifacts reduced this to 17,974 which was further reduced to 435 using the the ACMG group of actionable germline genes. Finally, excluding silent and intronic variants and those present at >2% population frequency resulted in 44 germline variants. Manual review of this final set against public knowledgebases and predictive analysis identified 3 germline mutations warranting further investigation: an APC deletion, an MSH6 deletion, and a TP53 p.R280S mutation which is well-described as somatic but has not previously been shown to be germline. Further investigation confirmed the presence of familial adenomatous polyposis in the APC mutant patient, and strongly implicated Li-Fraumeni syndrome in the TP53 mutant patient, who had developed sarcoma and lymphoblastic leukemia before age 30. Conclusions: Sequential computational filters can effectively limit the germline variants identified during paired tumor/normal sequencing to levels amenable to clinicopathologic correlation. We suggest a proactive and interdisciplinary approach to address the issues of informed consent, patient education, and consensus review for incidental germline findings of potential importance.
Androgen Receptor Signaling Mediated By a Novel Fusion Mutant Discovered in Men With Castration-Resistant Prostate Cancer
Changxue Lu, Yan Chen, Mary Nakazawa, Jun Luo. Johns Hopkins University, Baltimore, MD. Background: Sustained androgen receptor (AR) signaling is a key determinant of castration resistance in men with advanced prostate cancer. Although multiple mechanisms underlying aberrant AR signaling have been characterized, a better appreciation of the diversity and heterogeneity of resistant mechanisms will require additional investigation. RNA sequencing has emerged as a major discovery platform for novel transcripts that may mediate aberrant AR activation in the castrate setting. Design: We performed RNA-Seq using metastatic castration-resistant prostate cancer (mCRPC) samples along with normal and tumor samples derived from untreated radical prostatectomies. Results: Here, we report the identification and characterization of a novel AR mutation identified in a metastatic tumor sample. This newly discovered AR mutant transcript is a fusion molecule containing AR exons 1, 2, and 3, followed by a 200bp sequence matched to a long interspersed elements L4 (LINE4) sequence distant from the AR gene locus. As a result, this novel fusion transcript encodes a truncated AR (called AR-L4) consisting of AR N-terminal domain, DNA-binding domain, and a variantspecific peptide sequence. We have extanded the expression analysis of this novel fusion transcript in a set of mCRPC specimens. Although the overall frequency is low, AR-L4 is a recurring mutant. AR-L4 is mainly localized in the nuclei but also detected in the cytoplasm. By microarray analysis, AR-L4 is associated with at least 100 AR-related genes (including KLK3, NKX3.1, FASN, and TMPRSS2) in the absence of AR signaling mediated by the full-length AR, implicating a role in activating AR signaling when the full-length AR is potently inhibited by existing therapies. Conclusions: These findings underscore the importance of laboratory discovery efforts in uncovering mechanisms of drug resistance pertaining to the novel AR-targeting therapies including abiraterone and enzalutamide.
Over-Expression of S100A4 as Regulated By ß-Catenin Is Associated With a Higher Risk of Metastasis in Patients With Signet-Ring Cell Carcinoma
Yihong Ma, Gene Siegal, Shi Wei. University of Alabama, Birmingham, AL. Background: Aberrant expression of β-catenin, a key factor in Wnt signaling, plays a pivotal role in tumor progression and metastasis. S100A4, a downstream gene in the β-catenin/TCF transcription factor pathway, has well-established metastasis-promoting activity. As a small calcium binding protein, S100A4 drives metastasis by affecting the tumor microenvironment while stimulating cancer cell motility and invasion. It has been demonstrated that aberrant expression of β-catenin is associated with a higher risk of metastasis in signet ring cell carcinoma. The role of S100A4 is now further examined. Design: Forty-five cases of SRCC or carcinoma with prominent signet-ring features from various organ systems were retrieved from the authors' institution. The immunoexpression of β-catenin and S100A4 was examined. Nuclear/cytoplasmic subcellular localization of β-catenin was scored as demonstrating aberrant expression. At least a 25% increase in intensity of S100A4 was considered as positive when compared to normal tissue. Results: Among the 45 cases, 24 out of the 32 (75%) with aberrant expression of β-catenin had lymph node and/or distant metastasis while 5 out of 13 (38%) with membranous expression had metastasis (p<0.05). Thirty cases expressed aberrant β-catenin combined with increased S100A4 and 14 of these (47%) had metastasis. This is in contrast to the remaining 15 cases without aberrant β-catenin plus increased S100A4 where only 2 (13%) had metastasis (p<0.05).
Conclusions: SRCCs with combined aberrant β-catenin and increased S100A4 had a higher rate of metastasis (Pearson Chi-Square p=0.0463). This finding not only provides new insight into the role of the Wnt/β-catenin pathway in the progression and metastasis of SRCCs but also has implications for therapeutic targeting and functional blockade. Background: Next generation sequencing (NGS) has provided enormous insight into the genomic landscape of several tumor types, illuminating molecularly-defined subtypes, identifying new druggable targets and providing insights into heterogeneity and evolution of many tumors. Various NGS assays are starting to translate into clinical practice. We describe our multi-disciplinary WES-based Precision Medicine program designed to aid in therapeutic decision making and fuel translational research. Design: Metastatic and treatment resistant cancer patients are prospectively enrolled for paired metastatic tumor and germline WES. Using a comprehensive computational pipeline, point mutations, indels and copy number alterations are detected. Mutations are categorized in Category I-III based on actionability, and a report is generated and discussed in tumor board. Patients are followed prospectively for correlation of molecular information with clinical response and patient outcomes. A rapid response functional team was established to follow up on key findings to expand actionability based on the WES results. Results: In the first year, 156 tumor-germline pairs from 97 patients were sequenced with an average coverage of 95x and 16 mutations detected per patient. Among these, 16 were Category I, 98 were Category II and 1,474 were Category III. Tumor purity ranged from 14-100%. An unexpected finding, a prostate cancer "exceptional responder" was identified that harbored a somatic hemizygous deletion of the DNA repair gene FANCA and likely loss of function of the second allele through germline missense variant. Follow-up experiments established that loss of FANCA function was associated with platinum hypersensitivity in vitro and in a patient derived xenograft, thus providing biologic rationale for his extreme clinical response. Conclusions: Understanding molecular mechanisms of response and resistance to anticancer therapies requires prospective patient follow-up and clinical and functional validation of both common and low frequency mutations. We describe a multidisciplinary precision medicine program designed to bring WES into clinical practice and illustrate how this can be utilized to identify novel predictive biomarkers associated with exceptional systemic response. Smita Patel, Lela Buckingham, Aparna Harbhajanka, William Barbanera, Diana Murro, Vijaya Reddy, Ritu Ghai, Pincas Bitterman, Paolo Gattuso. Rush University Medical Center, Chicago, IL. Background: Pulmonary hamartomas (PHs) are benign clonal neoplasms. Although PHs do not transform to malignancy, high frequency of coexistence of PHs and lung cancer has been reported. Epigenetic alterations such as abnormal DNA methylation are associated with many human cancers. In previous study, we found that APC and RASSF1 methylation levels were generally higher in tumors without associated PHs than tumors with PHs, but not significantly. The aim of the present study is to investigate APC promoter hypermethylation in PHs coexistent with lung cancer. Design: We evaluated APC promoter methylation levels in 52 patients diagnosed with PH from 1993 to 2014. APC gene promoter methylation was quantified using pyrosequencing.
Precision Cancer Medicine Program for Whole Exome Sequencing (WES) of Metastatic Tumors Reveals Biomarkers of Response
Adenomatous Polyposis Coli (APC) Promoter Hypermethylation in Pulmonary Hamartomas Contributing To a Malignant Phenotype
Results: Among 52 patients, there were 26 males and 26 females with mean age of 63 (range 35-90 years). Thirty of 52 (58%) PHs were without associated cancer, 13 of 52 (25%) PHs had coexistent lung cancer and 9 of 52 (17%) PHs had cancer in other organs other than the lung. The coexistent lung cancer includes: adenocarcinoma (8), squamous cell carcinoma (2), mesothelioma (1), small cell carcinoma (1), and lymphoma (1). Ten of 13 (77%) patients who had PHs with lung cancer showed same lobe involvement and 11 of 13 (85%) had synchronous lung cancer. The average percent promoter methylation in APC was higher in PHs with associated cancer than those without (p= 0.002). A significant level of hypermethylation is found at CpG sites 148 (p=0.02), 129 (p=0.001) and 113 (p=0.02) bp upstream of exon 1. At the CpG site 129 bp upstream of exon 1, 8 of 13 (62%) PHs with associated lung cancer showed hypermethylation as compared to 9 of 30 (30%) PHs without associated lung cancer. We also found an interesting association of APC hypermethylation in PHs with other cancers including known breast (2), colon (1), prostate (1), kidney (1), liver (1) and sarcoma (2). All the patients (9/9) among this group showed hypermethylation of APC (p= 0.002).
Conclusions:
Although pulmonary hamartomas are benign neoplasms, there is an associated increased risk of cancer and warrants thorough clinical work-up. To our knowledge, these are the first studies to evaluate the epigenetic characteristics of PHs and association with cancer. A significant percentage of PHs associated with cancer including lung and other organs show APC promoter hypermethylation at specific CpG sites. Promoter methylation of APC in PHs provides the tumoral background possibly by contributing to a general loss of cell cycle control and aberrations in other cell functions.
BK Virus PCR Testing in Kidney Transplant Patients
Paul Persad, Elizabeth Palavecino. Wake Forest University Baptist Medical Center, Winston-Salem, NC. Background: BK virus associated nephropathy (BKVAN) develops in 8-10% of renal transplant recipients. Although often asymptomatic, signs and symptoms may include fever, hematuria or elevated creatinine. Fifty to 80% of those who develop BKVAN progress to graft dysfunction or failure. The gold standard for diagnosing BKVAN is the kidney biopsy. Immunohistochemistry for Simian Virus 40 (SV40) can be performed for confirmation in difficult cases. Unfortunatley histologic changes may be evident only after infection is well established. The presence of virus in the urine and blood often precedes the nephropathy by several months, can be easily detected by polymerase chain reaction (PCR), and may predict the development of BKVAN. Design: The Wake Forest University Baptist Medical Center kidney transplant records were reviewed from January 2013 to April 2014 to identify a correlation between elevated viral levels in urine (>10,000 copies per milliliter) or blood (>500 copies per milliliter) and BK virus activity in kidney biopies. SV40 immunohistochemistry was performed on formalin fixed parafin embedded (FFPE) tissue in search of viral replication not identifed by routine light microscopy. Results: Twenty kidney transplant recipients who developed BK viuria ranging from less than 500 to greater than 50 million copies per milliliter or viremia ranging from less than 500 to greater than 200,000 copies per milliliter were identified. None of the identified cases demonstrated evidence of BK virus replication in the renal parenchyma either by conventional histology or immunohistochemistry. Conclusions: Despite development of viremia or viuria no evidence of viral activity could be found via routine histologic examination or immune methods. The most common diagnosis at kidney biopsy was acute tubular necrosis and preexisting disease (e.g. diabetes, hypertension NR27, BAT25, BAT26). IHC revealed loss of MMR in 23% of CRC and 29% of EC. PCR results were correlated with IHC fi ndings to identify the optimal criterion for identifying MSI in EC. Results: Median cumulative BPS for all markers were 2 and 6 in MSI positive EC and CRC, respectively. BAT26 was the most sensitive (100%) and specifi c (95%) microsatellite for both EC and CRC. Defi ning MSI as ³1 BPS in ³3 loci demonstrated optimal sensitivity (97%) and specifi city (99%) for detecting MSI in EC. This criterion also demonstrated 100% sensitivity and 99% specifi city in CRC. Using ³3 BPS in ³2 loci failed to identify 16/37 EC and 1/25 CRC with loss of MMR, with four of the 16 EC showing loss of MSH6. Our revised criteria for MSI correctly identifi ed all but one EC with loss of MRR.
Conclusions:
We have found that the accepted threshold for classifi cation of MSI is suffi ciently sensitive and specifi c in CRC. However, based on our fi ndings small BPS in EC often do correlate with loss of MMR proteins by IHC, and may be missed by laboratories only utilizing PCR to screen for LS. Based on our data, this practice may result in erroneously designating 43% of EC as MSS. Many of these cases showed loss of MSH6 by IHC, characteristic of LS. This represents a pitfall in the screening for LS by MSI evaluation. We speculate that the decreased sensitivity of MSI evaluation in EC results from the earlier presentation and biopsy of these tumors over CRC, although further studies and clinical correlation are required.
COMPAREDx: A Prospective Study Comparing Molecular Versus Histopathologic Accuracy in the Classifi cation of Metastatic Tumors
Daniel Rosen, Harris Soifer, Yaeli Bierman Harrar, Federico Monzon, Catherine Schnabel. Baylor College of Medicine, Houston, TX; bioTheranostics, San Diego, CA. Background: Accurate tumor classifi cation is essential to the application of biomarker testing and individualized care. Alongside the reported limitations of traditional methods of tumor classifi cation such as IHC, there is an increasing requirement for molecular characterization of cellular context to enable precision medicine. Gene expression-based profi ling is a validated technology for molecular classifi cation of tumors, with reported accuracies in the range of 80% -90%, and initial studies have demonstrated its improved diagnostic accuracy versus IHC. In addition, inter-pathologist concordance has not been comprehensively characterized across a wide range of tumors in a systematic manner.
The aim of COMPAREDx is to characterize key issues along the spectrum of diagnostic ambiguity such as inter-pathology concordance, limitations of IHC, and the integration of molecular profi ling, with the goal to improve diagnostic certainty. Design: This is a prospective, blinded study of approximately 400 cases, designed with two main objectives: 1) Determining the non-inferiority, and potential superiority, of molecular tumor classifi cation by the 92-gene assay versus IHC across a study population of tumor types that consists of 96% of cancers based on incidence and 2) To characterize inter-pathologist concordance in diagnoses.
Results:
The study utilizes a landmark approach through the creation of a web-based, digital pathology interface linked to a scalable database containing the results of 76 different IHC markers per case. The ability to interpret the IHC results in real-time will maintain the diagnostic continuity and permit the accurate capture of diagnostic certainty data through survey-based questions at the end of each case. The COMPAREDx web interface allows for remote access and review, and will evaluate the impact of differences in clinical experience, region, and practice setting on diagnostic accuracy.
Conclusions:
COMPAREDx is a comprehensive comparator study measuring the diagnostic accuracy of immunohistochemistry vs a molecular 92-gene RT-PCR assay for the classifi cation of a broad range of solid tumor types. The COMPAREDx web portal is a novel and scalable resource for assessing important parameters in diagnostic accuracy and diagnostic decision-making for poorly differentiated and metastatic tumors. Jeffrey Ross, Kai Wang, Juliann Chmielecki, Siraj Ali, Julia Elvin, Roman Yelensky, Doron Lipson, Vincent Miller, Philip Stephens. Albany Medical College, Albany, NY; Foundation Medicine Inc, Cambridge, MA. Background: BRAF, a member of the RAS/RAF/MEK signaling pathway, has emerged as a major oncogenic driver and a potential target of therapy in a wide variety of solid tumors and hematological malignancies. BRAF V600E is an approved target for the BRAF inhibitors dabrafenib and vemurafenib in melanoma. BRAF gene fusions, which have been described in several solid tumor types, however, represent a different mechanism of BRAF activation. The use of targeted therapies against these BRAF fusion alterations has been limited despite their potential as a promising drug target. which can be abrogated with MEK and CRAF inhibition. Clinical evidence of sensitivity of these BRAF fusions to the pan-kinase inhibitor sorafenib and other targeted therapies in combination with chemotherapy will be presented. Conclusions: BRAF fusions are a rare driver alteration that develop in a wide variety of malignant neoplasms. BRAF fusions are most commonly encountered in gliomas, melanomas and NSCLC and appear to be associated with specifi c histologic subsets. Preliminary evidence suggests that BRAF gene fusions can be successfully targeted with pan-kinase and MEK inhibitors. There is a trend towards lower stage in UM tumors. While the average mutation counts in the MS stable (MSS) cancers (n=152) are 4.8 fold lower than in the MSI cancers (n=56, p=1.10×10 -7 ), no difference exists when POLE is mutated (p = 1). The POLE mutation status does not improve OS in the MSS or MSI groups (p=0.8).
BRAF Gene Fusions Occur Across a Diverse Subset of Human Solid Tumors and Respond To RAF Kinase Inhibitors
POLE Expression and Integrative Genomic Characterization in
Conclusions: POLE is constitutively expressed in CRC. The survey IHC suggests that POLE may not cause loss of the POLE protein; however, this requires further study of more tumors of known POLE status, using additional antibodies. POLE mutations increase mutation rates in both MSS and MSI tumors, but not all POLE mutated tumors are UM. Further study is needed on the impact of POLE mutation on prognosis.
Differences in Biological Properties and Clinical Features of KRAS and GNAS Oncogenes in Pancreatic Cystic Disease
Angela Sanguino Ramirez, Jan Silverman, Sydney Finkelstein. Allegheny General Hospital, Pittsburgh, PA; RedPath, Pittsburgh, PA. Background: Pancreatic cysts, a potential early stage of pancreatic neoplasia, are increasingly recognized by radiologic imaging. Molecular testing of cyst fl uid is an ancillary test that can help guide clinicians into appropriate management and treatment. Mutations of GNAS and KRAS are commonly seen in pancreatic cysts and are considered markers associated with potential malignant behavior. The aim of the study was to identify pathobiological differences in pancreatic cysts harboring GNAS and/or KRAS mutations. Design: We analyzed data on pancreatic cyst fl uids that were initially classify as indeterminate by cytology and radiology. We examined the associations between the presence or absence of KRAS and/or GNAS mutations and the occurrence of other indicators suggestive for carcinoma: 1)high CEA; 2)imagining with worrisome features for malignancy; 3)high DNA quantity; 4)non-degraded DNA; 5)cytology reported as "atypical" and 6)loss of heterozygosity (LOH). A pancreatic cyst with mutations of KRAS and/or GNAs and two or more additional indicators for malignancy were considered highly suggestive for aggressive behavior.
Results:
We reviewed a total of 1036 pancreatic cyst fl uids received in the last two years. Among these patients, 210 (16%) revealed mutations of KRAS, 84 (6%) mutations of GNAS and 119 (9%) mutations of both KRAS and GNAS. Pancreatic cysts with KRAS mutation were more often associated with presence of two or more additional criteria for aggressive behavior (table 1) . This association was not identifi ed with GNAS mutations, and interestingly, neither with the presence of both GNAS and KRAS mutations. Pancreatic cysts with KRAS mutations were more likely to exhibit high DNA content and presence of LOH. 
Conclusions:
To the best of our knowledge, this is the first study to provide evidence that suggests pancreatic cysts with GNAS and KRAS mutations are biologically and clinically different, with cysts having GNAS mutations behaving in a less aggressive fashion. We believe that our findings could guide clinicians into more personalized management of patients with pancreatic cysts based on the molecular findings. However, further studies including patient outcomes would be helpful in confirming these findings. Results: Analysis of global cellular DNA methylation identified over 13,000 differentially methylated CpG residues in cells exposed to EBV compared to uninfected controls. 65 cellular genes that acquired CpG methylation showed altered transcript levels. Genes with increased transcript levels frequently acquired DNA methylation within the gene body while those with decreased transcript levels acquired DNA methylation near the transcription start site. Treatment with the DNA methyltransferase inhibitor restored expression of some hypermethylated genes. Cytogenetic analysis does not show chromosomal alterations in EBV-positive and EBV-negative transientlyinfected clones compared to uninfected controls. Conclusions: Our observations suggest that EBV infection resulted in a cellular epigenetic reprogramming that was retained after loss of the virus. EBV infection is able to reshuffle the cellular epigenome and have long lasting consequences as a mechanism for hit-and-run oncogenesis. Unlike genetic alterations, these epigenetic changes can be reversed pharmacologically, providing therapeutic interventions to EBV-associated malignancies. We showed that platelet cloaking of cancer cells is universal, occurring across all 7 tumour types examined. However, it is heterogeneous with adhesion rates varying both across and within tumour types, from 34% (C33a-primary cervical cancer) to 83% (SKMES1-metastatic lung cancer). Changes indicative of EMT were seen in all cell lines. However, again they were heterogeneous in nature; with morphology changes akin to EMT observed at varying degrees across the cancer types. Also, there was no consistent pattern to the EMT-like gene expression changes seen. WTA showed that while there was a greater number of gene expression changes in SKOV3 cells (>32%), the biological processes affected in both cell lines were similar. We identified 30 genes that were commonly affected in both cell lines. Many of these 30 genes form part of an interlinking pathway, that is regulated by TGFß1 and associated with cell adhesion and ECM remodelling.
EBV Infection of Oral Keratinocytes Leads To a Cellular Epigenetic
Conclusions:
For the first time, we describe the universal nature of platelet cloaking and its role in driving metastasis. Additionally, we have identified a set of 30 genes that hold potential to be in vivo markers of this interaction and also therapeutic targets, allowing the establishment of therapies tailored to inhibit metastasis. Cervicospheres were generated and they showed upregulation of VIMENTIN, NANOG, TWIST, SNAIL and SLUG transcripts as compared to differentiated cells indicating that they were enriched for CSC. The cervicospheres showed 2-6 fold upregulation of CD49f and CD133. Cells were sorted into ALDH+ and ALDH-cells by FACS followed by screening for cell surface markers. CD133 was >20 fold upregulated in ALDH+ cells.
CD133 Is a Putative Cell Surface Marker of Cancer Stem Cells (CSC) in Squamous Cell Carcinoma of the Uterine Cervix
In 16 tumor samples of cervical squamous cell carcinoma, CD133 positivity by flow cytometry ranged from 1.3-23% of the total population. Conclusions: CD133 is a putative marker of Cancer stem cells in squamous cell carcinoma of the uterine cervix. Identification of a surface marker will enable further studies to discern the clinical significance of CSC in cervical cancer. candidates for targeted therapy. Sebaceous carcinoma (SC) is an aggressive cancer. Its benign counterpart, sebaceous adenoma (SA), is a cutaneous marker of microsatellite instability (MSI) in some patients with Muir-Torre syndrome (MTS). The moleculargenetic alterations contributing to the pathogenesis of SC and SA (sporadic versus MTS) remain poorly understood, but given the high morbidity and mortality of SC and MTS, there is a critical need to delineate the pathways driving these tumors and candidates for targeted therapy. We describe differentially expressed miRNAs in a series of periocular SC compared to SA and among SA (MTS versus sporadic). Design: 30 SC and 23 SA (including 8 confirmed MTS and 8 confirmed sporadic SA) were profiled. Using total RNA from formalin-fixed paraffin embedded tissue, real-time RT-PCR was performed in a microfluidics card containing 378 unique miRNAs. Foldchange was determined using ∆∆Ct method (reference: RNU48). Median centering normalized the data. Two-sample t-tests identified differentially expressed miRNAs. False discovery rate was assessed by beta uniform mixture analysis of p-values from the t-statistics. Significance was defined by this estimated false discovery rate. Results: Serial testing and validation confirmed a statistically significant overexpression of oncogenic miRNAs in SC versus SA: miR-486-5p (3.8 fold; p=1.7e -6 ) and miR-184 (2.8 fold; p=3.0e -4 ), and down-regulation of tumor-suppressive miRNAs: miR-211 (-6.8 fold; p=5.8e -10 ) and miR-195 (-2.5 fold; 5.2e -7 ). In MTS-SA versus sporadic SA, we show over-expression of miR-10b (2.1 fold; p=6.2e -3 ) and miR-10a (2.6 fold; p=1.1e -2 ) and down-regulation of miR-518f (-5.32 fold; p=7.4e -3 ), miR-192 (-0.95 fold; p=1.4e -2 ) and miR-126 (-1.2 fold; p=2.8e -2 ). Conclusions: SC exhibits a distinctive miRNA expression profile from SA, implicating dysregulation of NFkB and PTEN (targets of miR-486-5p) and epithelial to mesenchymal transition (target of miR-211) in the genesis of SC. Further, MTS-SA show down-regulation of miR-192 and miR-126-both similarly changed in MSIhigh colorectal carcinomas. miRNAs provide a novel entry point for a comprehensive understanding of the molecular-genetic alterations central to the development of SC and SA. Background: Prostate cancer molecular subtypes based on ETS gene fusions and SPINK1 were originally identified through distinct gene expression profiles. Such molecular subtypes may have utility in disease stratification and clonality assessment, complementing available purely prognostic tests. Hence, we determined the validity of molecular subtyping using global gene expression profiles. Design: We analyzed 1,577 patient Affymetrix Human Exon 1.0ST GeneChip expression profiles from 8 RP cohorts. Multi-feature random forest classifiers and outlier analysis were used to define molecular subtypes. Results: A random forest (RF) classifier was trained and validated to predict ERG status (m-ERG) using atraining subset with known ERG rearrangement status, achieving >95% sensitivity and specificity in the validation subset. The model was then applied to 7 independent RP cohorts to predict ERG rearrangement status. Less frequent rearrangements involving other ETS genes (ETV1,4,5, FLI1) or SPINK1 overexpression were predicted based on gene expression outlier analysis. Across cohorts, 45%, 9% 8% and 38% of PCa were classified as ERG+, ERG-ETS+, ERG-SPINK+, and Triple Negative (ERG-/ETS-/SPINK1-), respectively. Results show that the four subtypes could be collapsed into three entities (ERG+, ERG-/ETS+ and SPINK+/Triple Negative) based on shared expression patterns and clinical characteristics. Based on MVA logistic regression analysis, m-ERG+ status was significantly associated with lower pre-operative serum PSA (p<0.001), lower Gleason score (p=0.001), the presence of extraprostatic extension (p<0.001) and white Caucasian race (p=0.001).
Conclusions:
The DECIPHER test platform can accurately determine ERG status and PCa molecular subtypes. Inclusion of molecular subtyping, such as m-ERG status, may enable additional precision medicine opportunities in prognostic tests.
Molecular Traits of Tumors From Patients Status Post Solid Organ Transplant
Chad Vanderbilt, Daniel Merrick. University of Colorado, Aurora, CO. Background: The immunosuppression associated with solid organ transplant (SOT) is known to increase the risk for developing malignancy. While infection-related malignancies are relevant to the increased risk, the rate of certain epithelial malignancies without known infectious etiology is also increased in SOT patients. This observation provoked us to hypothesize that epithelial tumors arising in SOT patients have unique molecular profiles. Design: To identify SOT patients, we queried the clinical laboratory data warehouse to pinpoint patients who had been tested for serum tacrolimus from the period of April 2010 through August 2014. We then cross referenced these patients with the patients who had molecular testing performed between January 2012 and August 2014. We identified the molecular and clinical characteristics of the SOT cohort patients. We also compiled a control group (N=82) consisting of patients with targeted next generation sequencing (TNGS) performed on colorectal carcinoma (CRC). Results: The molecular testing performed was a combination of targeted single gene sequencing (TSGS) (57%) and TNGS (43%). TNGS yielded an increase in mutation frequency compared to TSGS: 4 mutations per tumor tested versus 0.25. The mutation frequency of the patients with SOT tested with TNGS was increased 33% over the control group (4.0 vs. 3.0, p=NS). Notably there was one SOT patient with CRC yielding 11 mutations, the highest number of mutations for any tumor tested in our laboratory.
Conclusions: This study shows that cross-referencing separate databases is a high-yield method for identifying specific patient populations. While the sensitivity is unknown the specificity is 100%. Our results point toward a trend in increased mutation frequency in SOT patient malignancies. The results support our hypothesis that the mutation profile of tumors arising in patients with SOT is unique and that TNGS can be utilized to further characterize differences in these tumors.
Differentially Expressed MicroRNAs and Their Targeted mRNAs in Ovarian Carcinoma and Associated Endometriosis
Richard Wu, Baraa Alosh, Sudeshna Bandyopadhyay, Eman Abdulfatah, Haleema Saeed, Kinda Hayek, Robert Morris, Adnan Munkarah, Rouba Ali-Fehmi. Wayne State University, Detroit, MI. Background: In a previous study, we identified significantly distinct oncogenic miRNAs and tumor suppressor (TS) miRNAs distinguishing ovarian cancer (OC) from endometriosis (EM) by comparing the comprehensive miRNA profiling of OC and associated EM. The relative changes of these miRNAs are verified using qRT PCR. However, the affect of miRNAs on ovarian carcinogenesis remains unclear. The study aimed to identify the downstream mRNA targets of these miRNAs and verify their alterations by real time PCR. Design: Foci of EM and concurrent OC in 19 cases were microscopically selected and macro-dissected from FFPE sections, after review of the corresponding H and E slides. The comprehensive miRNA expression profiling of OC and EM were performed initially from pooled RNA samples from all 19 cases through LC Sciences using array technology. This was followed by quantitative real time RT-PCR (qRT-PCT) to verify the abnormal expression of selected miRNAs. The downstream mRNAs of these miRNAs were identified with ingenuity pathway analysis. The 2 most important mRNAs(PTEN and NTKB) were further analyzed by RT-PCR.
Results:
The miRNA profiling demonstrated deregulation of over 1000miRNAs in OC of which, the top seven were further validated by qRT-PCR. The expression of TS miRNAs miR-1, miR-133a, and miR-451 were reduced significantly in OC while in oncogenic miRNAs miR-141, miR-200a, miR-200c, and miR-3613 was elevated significantly in OC as shown in fig 1 and 2. After IPA (ingenuity pathway analysis), the 2 most significant target mRNAs of these miRNAs: PTEN and NFKB were selected. The expression of their mRNAs were verified by qRT-PCR. PTEN mRNA was decreased significantly in the OC compared to the EM foci while NFKB mRNA has no statistically significant changes in these two entities as shown in fig 3. Conclusions: Significant differences exist between the malignant OC and its benign associated EM at the level of miRNA and mRNA transcription. Both TS miRNA(1,133a,451) and oncogenic miRNAs (141,200a,200c,3613) are possible molecules to distinguish OC from its associated EM. These miRNAs should be studied further to identify their roles as possible biomarkers in the diagnosis of OC. These miRNAs and mRNAs could also serve as therapeutical targets due to its distinctive expression patterns in malignant OC.
FOXO1/Sprouty2 Pathway Regulates Vascular Tumor Growth
Wei Xie, Sriram Ayyaswamy, Wa Du, Thuy Phung. Texas Children's Hospital, Houston, TX.
Background: Vascular tumors are neoplasms of endothelial cells with a wide clinical presentation, ranging from benign infantile hemangioma and low-grade malignant hemangioendothelioma in children to malignant angiosarcoma in adults. To date, the molecular basis of vascular tumor pathogenesis is poorly understood and standard therapies, particularly those for malignant lesions, have limited clinical efficacy. Forkhead box protein O1 (FOXO1) is transcription factor with tumor suppressor function and is dysregulated in human cancer. In this study, we showed that FOXO1 suppressed vascular tumor growth, and mechanistically, the inhibitory effects of FOXO1 were mediated by the downstream effector Sprouty2. Design: The expression of FOXO1 and Sprouty2 was examined in infantile hemangioma, hemangioendothelioma and angiosarcoma tissues by immunohistochemical stains. Loss-and gain-of-function studies of FOXO1 and Sprouty2 were performed by using short-hairpin RNA to knockdown gene expression, and by transfecting cells with cDNA plasmids to overexpress a gene. Cell migration and proliferation were assessed by scratch area closure and cellular DNA content, respectively. Results: FOXO1 expression was reduced in a variety of human vascular tumors examined (infantile hemangioma, hemangioendothelioma and angiosarcoma) as
